Acadia Pharmaceuticals, Inc. (ACAD) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
